key: cord-0787969-odt4g1zx
authors: Borgmann, Hendrik; Höfner, Thomas; Sasca, Daniel; Porubsky, Stefan; Tsaur, Igor; Haferkamp, Axel; Dotzauer, Robert
title: Pandemic Spread of COVID-19 Mutant Variants Will Facilitate Next-generation Sequencing Capacities for Personalised Medicine in Urologic Oncology
date: 2021-02-25
journal: Eur Urol
DOI: 10.1016/j.eururo.2021.02.037
sha: 12f1b27bb1495dc07c2c35d7fa0d09cf54e0639a
doc_id: 787969
cord_uid: odt4g1zx

nan

metastatic PCa [3] . Moreover, men with localised PCa should also be considered for germline testing if at least two close blood relatives on the same side of the family have been diagnosed with tumours linked to hereditary cancer predisposition syndromes.

We investigated the global preparedness for performing NGS for PCa patients and hypothesised that preparedness might differ between continents. To quantify the relationship between NGS capacity and PCa incidence, we retrieved NGS market size data from 2020 for Africa, Asia-Pacific, Europe, Latin America, and North America [4] and estimated new PCa cases in 2020 for these continents from the WHO global cancer observatory [5] . We then calculated the preparedness ratio for NGS in PCa patients using the following formula: As it has already been predicted that the global NGS market will grow by an annual compound growth rate of 19%, reaching US$ 8.5 billion by 2025, these numbers will probably be surpassed because of increasing demand for NGS testing for COVID-19 mutant variants. This increased demand for the NGS market will result in increased capacities and once the pandemic has resolved and the demand drops, costs for NGS in personalised medicine in urologic oncology will decrease. While global new cases of prostate (1 414 259), bladder (573 278), kidney (431 288), testis (74 458), and penile cancers (36 068) amount to 2 529 351 million new cases for genitourinary malignancies in 2020, our data show that the ensuing lower costs for NGS will facilitate and accelerate the integration of personalised medicine in urologic oncology care.

The authors have nothing to disclose. 

Emergency Committee regarding the coronavirus disease (COVID-19) pandemic 2021. www.who.int/news/item/15-01-2021-statement-on-the-sixthmeeting-of-the-international-health-regulations

Olaparib for metastatic castration-resistant prostate cancer

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Global next-generation sequencing market size, share, trends, growth analysis report -segmented by product, technology, application and regionindustry forecast

World Health Organization. Global cancer observatory 2021